EBITDA

The deal sees CPM and MW Components move to UK-based Rosebank Industries, marking a major exit for the private equity firm and a strategic US expansion.

A new multi-year deal with XCharge will bring 400kW ultra-fast chargers to EnBW's network, aiming for enhanced reliability and European-made hardware.

Amid a booming gene therapy market, Oxford Biomedica Solutions launches key investor events to showcase its strategy and secure its leadership position.

A new report shows fraud fears in private credit are soaring, fueled by AI and bankruptcies, but data reveals a different story for secured lenders.

Axxess's upcoming conference tackles AI's role in home health, unveils a new leadership certification, and honors an industry titan. Here's what it means.

The digital asset giant is delisting from Toronto to streamline costs, a move that reshapes its buyback plan and how Canadian investors trade its stock.

The private equity firm's carve-out of the world's largest coworking franchisor signals a major push to scale flexible workspaces for the hybrid era.

A novel inhaled RNA therapy for a specific group of cystic fibrosis patients gains EMA fast-track status, promising accelerated access to new treatment.

Ziff Davis nets a massive windfall by selling its Connectivity division, including Ookla and Speedtest, to Accenture in a deal reshaping network intelligence.

Modaxo's new brand, Aerivo, emerges from an ADB SAFEGATE acquisition, poised to enhance airport efficiency with its cloud-native Flightivity suite.

Proofpoint launches its AI-powered Nuclei Suite, offering enterprise-grade compliance tools to resource-strapped small and medium businesses.

A new global survey reveals a startling gap between knowing sleep is vital and getting quality rest. Technology tracks our every toss and turn, but is it helping?

Post-listing, the Swiss HealthTech firm pushes for US market expansion and European reimbursement, streamlining its focus on AI-powered brain health.

Sika's new partnership with Giatec integrates AI and sensors into concrete, promising greener, cheaper, and more efficient construction projects.

With a pivotal trial for pancreatic cancer looming, Immuneering will detail its novel 'Deep Cyclic Inhibitor' platform and strategy to investors.

The AI firm reports a major financial overhaul and key acquisitions, but faces declining revenue and operational losses. Is it poised for a 2026 rebound?

LendingTree posts a record $319.7M Q4 driven by its insurance arm, yet an adjusted loss spooks investors. Can its AI-powered strategy win them back?

Construction begins on a massive, privately funded sports and education campus in South Dade, promising economic revival and a new era for athletic talent.

Publishing giant convenes leaders to define standards for adaptive knowledge, tackling IP, trust, and the very future of reading in the age of AI.

Entrepreneur Daniel Gestetner discusses resilience, a $1B exit, and why true success isn't about winning at all costs in a revealing new podcast.